Table 1 Demographics
From: Late cardiotoxicity related to HER2-targeted cancer therapy
N (n total = 17) | |
|---|---|
Age at referral (median) | 58 (IQR 54–61) |
Age at cancer diagnose (median) | 50 (IQR 46–55) |
Women (%) | 16 (94%) |
Breast cancer (%) | 16 (94%) |
Gastric cancer (%) | 1 (6%) |
Baseline LVEF (mean) | 63.7 ± 6.0% |
Type of anti-HER2 therapy (%) | |
Trastuzumab only | 10 (59%) |
Pertuzumab + Trastuzumab | 5 (29%) |
TDM1 | 1 (6%) |
Tucanitib + Trastuzumab | 1 (6%) |
Concomitant systemic treatment | |
Capecitabine | 2 (12%) |
Tamoxifen | 2 (12%) |
Denosumab | 4 (24%) |
Cardiovascular risk factor (%) | |
Hypertension | 5 (29%) |
Diabetes | 2 (12%) |
Smoker/ex-smoker | 1 (6%) |
Obesity | 1 (6%) |
Prior anthracyclines exposure (%) | 8 (47%) |
Prior left chest radiotherapy (%) | 5 (29%) |
Other previous chemotherapy | |
Taxanes | 13 (76%) |
Fluoropyridines | 4 (24%) |
Cyclophosphamide | 1 (6%) |
Mitoxantrone | 1 (6%) |